AIMS: To investigate the association between tumour characteristics and HER-2/neu by immunohistochemistry in primary operable breast cancer. METHODS: The association between HER-2/neu and other clinicopathological factors was evaluated in 1362 consecutive patients with primary breast cancer treated between 2000 and July 2003 in one centre. Microscopic tumour size, tumour grade, lymph node status, patient's age, oestrogen receptor (ER), progesterone receptor (PR), and joint ER/PR status were evaluated, using the chi2 test for univariate analysis and logistic regression for multivariate analysis. The hormone receptors and HER-2/neu were studied immunohistochemically. Using the HER-2/neu DAKO scoring system, scores of 0, 1+, or 2+ were defined as negative and 3+ as positive. Data for DAKO scores 2+/3+ versus 0/1+ are also presented. RESULTS: Hormone receptor negative breast cancers were more often HER-2/neu positive than hormone receptor positive cancers, both for ER (28.7% v 6.8%) and PR (19.9% v 5.9%). In multivariate analysis, both ER, PR, and tumour grade were independently associated with HER-2/neu. In ER+ tumours, HER-2/neu overexpression was significantly lower in PR+ than in PR- cases (11.5% v 5.4%). HER-2/neu overexpression (2.7%) was lowest in the large subgroup of ER+PR+ tumours with low tumour grade (grade 1-2), comprising 46.1% of all patients. CONCLUSIONS: ER, PR, and tumour grade are independent predictors for HER-2/neu overexpression in women with primary operable breast cancer. ER and PR are negatively associated with HER-2/neu, whereas tumour grade is positively associated with HER-2/neu. In women with ER+ tumours, PR status also affects the likelihood of HER-2/neu expression.
AIMS: To investigate the association between tumour characteristics and HER-2/neu by immunohistochemistry in primary operable breast cancer. METHODS: The association between HER-2/neu and other clinicopathological factors was evaluated in 1362 consecutive patients with primary breast cancer treated between 2000 and July 2003 in one centre. Microscopic tumour size, tumour grade, lymph node status, patient's age, oestrogen receptor (ER), progesterone receptor (PR), and joint ER/PR status were evaluated, using the chi2 test for univariate analysis and logistic regression for multivariate analysis. The hormone receptors and HER-2/neu were studied immunohistochemically. Using the HER-2/neu DAKO scoring system, scores of 0, 1+, or 2+ were defined as negative and 3+ as positive. Data for DAKO scores 2+/3+ versus 0/1+ are also presented. RESULTS: Hormone receptor negative breast cancers were more often HER-2/neu positive than hormone receptor positive cancers, both for ER (28.7% v 6.8%) and PR (19.9% v 5.9%). In multivariate analysis, both ER, PR, and tumour grade were independently associated with HER-2/neu. In ER+ tumours, HER-2/neu overexpression was significantly lower in PR+ than in PR- cases (11.5% v 5.4%). HER-2/neu overexpression (2.7%) was lowest in the large subgroup of ER+PR+ tumours with low tumour grade (grade 1-2), comprising 46.1% of all patients. CONCLUSIONS: ER, PR, and tumour grade are independent predictors for HER-2/neu overexpression in women with primary operable breast cancer. ER and PR are negatively associated with HER-2/neu, whereas tumour grade is positively associated with HER-2/neu. In women with ER+ tumours, PR status also affects the likelihood of HER-2/neu expression.
Authors: D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton Journal: N Engl J Med Date: 2001-03-15 Impact factor: 91.245
Authors: M J Ellis; A Coop; B Singh; L Mauriac; A Llombert-Cussac; F Jänicke; W R Miller; D B Evans; M Dugan; C Brady; E Quebe-Fehling; M Borgs Journal: J Clin Oncol Date: 2001-09-15 Impact factor: 44.544
Authors: M Fernö; O Stål; B Baldetorp; T Hatschek; A C Källström; P Malmström; B Nordenskjöld; S Rydën Journal: Breast Cancer Res Treat Date: 2000-01 Impact factor: 4.872
Authors: Allan Lipton; S M Ali; K Leitzel; L Demers; V Chinchilli; L Engle; Harold A Harvey; C Brady; C M Nalin; M Dugan; W Carney; J Allard Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: Syed K Mohsin; Heidi Weiss; Thomas Havighurst; Gary M Clark; Melora Berardo; Le D Roanh; Ta V To; Zhang Qian; Zho Qian; Richard R Love; D Craig Allred Journal: Mod Pathol Date: 2004-12 Impact factor: 7.842
Authors: Valerie-Jeanne Bardou; Grazia Arpino; Richard M Elledge; C Kent Osborne; Gary M Clark Journal: J Clin Oncol Date: 2003-05-15 Impact factor: 44.544
Authors: Richard R Love; Nguyen Ba Duc; Thomas C Havighurst; Syed K Mohsin; Qian Zhang; David L DeMets; D Craig Allred Journal: J Clin Oncol Date: 2003-02-01 Impact factor: 44.544
Authors: C Barrios; J F Forbes; W Jonat; P Conte; W Gradishar; A Buzdar; K Gelmon; M Gnant; J Bonneterre; M Toi; C Hudis; J F R Robertson Journal: Ann Oncol Date: 2012-02-08 Impact factor: 32.976
Authors: Yongxian Ma; York Tomita; Anju Preet; Robert Clarke; Erikah Englund; Scott Grindrod; Shyam Nathan; Eliseu De Oliveira; Milton L Brown; Eliot M Rosen Journal: Mol Endocrinol Date: 2014-12
Authors: Ana María García Vicente; Angel Soriano Castrejón; Miguel Angel Cruz Mora; Ana González Ageitos; María del Mar Muñoz Sánchez; Alberto León Martín; Ruth Espinosa Aunión; Fernanda Relea Calatayud; Vicente Muñoz Madero; Ignacio Chacón López-Muñiz; Jose Manuel Cordero García; Germán Andrés Jiménez Londoño Journal: Eur J Nucl Med Mol Imaging Date: 2012-09-28 Impact factor: 9.236
Authors: Mothaffar F Rimawi; Priya B Shetty; Heidi L Weiss; Rachel Schiff; C Kent Osborne; Gary C Chamness; Richard M Elledge Journal: Cancer Date: 2010-03-01 Impact factor: 6.860